Alwyn Mwinga
Direktor/Vorstandsmitglied bei Drugs for Neglected Diseases initiative
Profil
Alwyn Mwinga is currently the Director at Drugs for Neglected Diseases initiative.
She has a graduate degree from the University of London and a graduate degree from the University of Zambia.
Aktive Positionen von Alwyn Mwinga
| Unternehmen | Position | Beginn |
|---|---|---|
Drugs for Neglected Diseases initiative
 Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | Direktor/Vorstandsmitglied | - |
Ausbildung von Alwyn Mwinga
| University of London | Graduate Degree |
| University of Zambia | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Drugs for Neglected Diseases initiative
Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | Health Technology |
